Neuca

Neuca Retained Earnings

The Retained Earnings of Neuca (NEU.WA) as of Nov 4, 2026 is 700.18 M PLN. In the previous year, Retained Earnings was 733.08 M PLN — a change of -4.49% (lower).

Retained Earnings

700.18 MPLN

YoY

-4.49%

Last updated:

Retained Earnings of Neuca is 2025 700.18 M PLN. Retained Earnings of Neuca was 2024 733.08 M PLN. It decreases by -4.49% lower compared to the previous year.

The Neuca Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2018
218.68 M PLN
Jan 1, 2019
281.43 M PLN
Jan 1, 2020
525.72 M PLN
Jan 1, 2021
614.42 M PLN
Jan 1, 2022
640.05 M PLN
Jan 1, 2023
657.31 M PLN
Jan 1, 2024
733.08 M PLN
Jan 1, 2025
700.18 M PLN
The Neuca Retained Earnings history
YEARRetained EarningsYoY
700.18 MPLN-4.49%
733.08 MPLN+11.53%
657.31 MPLN+2.70%
640.05 MPLN+4.17%
614.42 MPLN+16.87%
525.72 MPLN+86.81%
281.43 MPLN+28.70%
218.68 MPLN-11.01%
245.73 MPLN-1.36%
249.11 MPLN+18.38%
210.43 MPLN+26.16%
166.79 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuca Stock analysis

What does Neuca do? NEUCA SA generates revenue through the wholesale distribution of pharmaceutical products to pharmacies, leveraging its extensive network in the health market. The company also produces and sells its own branded drugs, supplements, and cosmetics, while offering clinical trials, telemedicine services, and IT solutions tailored for healthcare providers. Its e-commerce platform further supports the healthcare industry by enabling digital transactions for medical products and services. The primary buyers include pharmacies, healthcare institutions, and consumers seeking health-related products through online channels. NEUCA SA's business model integrates multiple revenue streams within the health sector, with a focus on both physical and digital distribution. The firm's own-brand products, such as pharmaceuticals and cosmetics, are sold directly to end-users and retail partners, while its IT solutions and telemedicine services target healthcare organizations. Clinical trials represent another key segment, attracting partnerships with research institutions and pharmaceutical firms. The company's operational scope spans from production to distribution, ensuring a comprehensive approach to healthcare market needs. The company's revenue is driven by its diversified portfolio, including drug distribution, branded product sales, and specialized services like telemedicine and clinical trials. Pharmacies remain the core customer segment for its wholesale operations, while e-commerce and IT solutions cater to a broader audience of healthcare providers and consumers. NEUCA SA's strategic positioning in the health market allows it to capitalize on multiple growth areas without relying on a single revenue source. Neuca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuca stock

Retained Earnings of Neuca is 700.18 M PLN in 2025.

Retained Earnings of Neuca changed from 733.08 M PLN to 700.18 M PLN, representing a -4.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings Neuca since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's Neuca historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Neuca

All Key Metrics — Neuca